Cutler Group LP United Therapeutics Corp Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$179.86 - $214.88 $71,944 - $85,952	-400 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$170.47 - $211.93 $68,188 - $84,772	400 New	400 $71,000
Q4 2020 Jan 21, 2021	SELL	$101.87 - $151.79 $91,683 - $136,611	-900 Closed	0 $0
Q2 2020 Jul 22, 2020	SELL	$92.74 - $125.82 $166,932 - $226,476	-1,800 Reduced 66.67%	900 $108,000
Q1 2020 May 07, 2020	SELL	$79.39 - $115.35 $71,451 - $103,815	-900 Reduced 25.0%	2,700 $256,000
Q4 2019 Feb 06, 2020	SELL	$78.31 - $95.34 $7,831 - $9,534	-100 Reduced 2.7%	3,600 $317,000
Q2 2019 Aug 09, 2019	BUY	$76.06 - $120.81 $281,422 - $446,997	3,700 New	3,700 $288,000
Q2 2018 Aug 10, 2018	SELL	$101.14 - $118.31 $252,850 - $295,775	-2,500 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$107.21 - $151.94 $218,601 - $309,805	2,039 Added 442.3%	2,500 $280,000
Q4 2017 Jan 17, 2018	SELL	$118.58 - $151.28 $381,709 - $486,970	-3,219 Reduced 87.47%	461 $68,000
Q3 2017 Oct 17, 2017	BUY	$114.6 - $136.81 $421,728 - $503,460	3,680	3,680 $431,000

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.